Literature DB >> 12629257

Minocycline for Huntington's disease: an open label study.

Raphael M Bonelli1, Clemens Heuberger, Franz Reisecker.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12629257     DOI： 10.1212/01.wnl.0000049936.85487.7a

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  11 in total

1.  Lack of minocycline efficiency in genetic models of Huntington's disease.

Authors:  Stéphane Mievis; Marc Levivier; David Communi; Gilbert Vassart; Jacques Brotchi; Catherine Ledent; David Blum
Journal:  Neuromolecular Med       Date:  2007       Impact factor: 3.843

Review 2.  Apoptotic cascades as possible targets for inhibiting cell death in Huntington's disease.

Authors:  Lindsay R Pattison; Mark R Kotter; Dean Fraga; Raphael M Bonelli
Journal:  J Neurol       Date:  2006-09-22       Impact factor: 4.849

Review 3.  Update on Huntington's disease.

Authors:  Sarah B Berman; J Timothy Greenamyre
Journal:  Curr Neurol Neurosci Rep       Date:  2006-07       Impact factor: 5.081

Review 4.  Prospects for minocycline neuroprotection.

Authors:  Jennifer M Plane; Yan Shen; David E Pleasure; Wenbin Deng
Journal:  Arch Neurol       Date:  2010-08-09

5.  Comprehensive behavioral testing in the R6/2 mouse model of Huntington's disease shows no benefit from CoQ10 or minocycline.

Authors:  Liliana B Menalled; Monica Patry; Natalie Ragland; Phillip A S Lowden; Jennifer Goodman; Jennie Minnich; Benjamin Zahasky; Larry Park; Janet Leeds; David Howland; Ethan Signer; Allan J Tobin; Daniela Brunner
Journal:  PLoS One       Date:  2010-03-22       Impact factor: 3.240

6.  Feasibility of minocycline and doxycycline use as potential vasculostatic therapy for brain vascular malformations: pilot study of adverse events and tolerance.

Authors:  Tim Frenzel; Chanhung Z Lee; Helen Kim; Nancy J Quinnine; Tomoki Hashimoto; Michael T Lawton; B Joseph Guglielmo; Charles E McCulloch; William L Young
Journal:  Cerebrovasc Dis       Date:  2008-01-23       Impact factor: 2.762

Review 7.  Brain arteriovenous malformation modeling, pathogenesis, and novel therapeutic targets.

Authors:  Wanqiu Chen; Eun-Jung Choi; Cameron M McDougall; Hua Su
Journal:  Transl Stroke Res       Date:  2014-04-12       Impact factor: 6.829

Review 8.  Drug repositioning for Alzheimer's disease.

Authors:  Anne Corbett; James Pickett; Alistair Burns; Jonathan Corcoran; Stephen B Dunnett; Paul Edison; Jim J Hagan; Clive Holmes; Emma Jones; Cornelius Katona; Ian Kearns; Patrick Kehoe; Amrit Mudher; Anthony Passmore; Nicola Shepherd; Frank Walsh; Clive Ballard
Journal:  Nat Rev Drug Discov       Date:  2012-11       Impact factor: 84.694

9.  A randomized double-blind, placebo-controlled trial of minocycline in children and adolescents with fragile x syndrome.

Authors:  Mary Jacena S Leigh; Danh V Nguyen; Yi Mu; Tri I Winarni; Andrea Schneider; Tasleem Chechi; Jonathan Polussa; Paul Doucet; Flora Tassone; Susan M Rivera; David Hessl; Randi J Hagerman
Journal:  J Dev Behav Pediatr       Date:  2013-04       Impact factor: 2.225

10.  Minocycline attenuates cognitive impairment induced by isoflurane anesthesia in aged rats.

Authors:  Feijuan Kong; Shuping Chen; Yuan Cheng; Leilei Ma; Huishun Lu; Honghai Zhang; Wenwen Hu
Journal:  PLoS One       Date:  2013-04-17       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.